

AD _____

(Leave blank)

Award Number:

W81XWH-04-1-0490

TITLE:

Polychlorinated Biphenyls, Organochlorines & PD Risk: A Case Control Study in Alaskan Natives

PRINCIPAL INVESTIGATOR:

Caroline M. Tanner, M.D., Ph.D.

CONTRACTING ORGANIZATION:

**Parkinson's Institute
Sunnyvale, CA 94085**

REPORT DATE:

May 2011

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

- ☒ Approved for public release; distribution unlimited
- ☐ Distribution limited to U.S. Government agencies only; report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.				
1. REPORT DATE (DD-MM-YYYY) 01-MAY-2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 01 APR 2010 - 1 APR 2011
4. TITLE AND SUBTITLE Polychlorinated Biphenyls, Organochlorines & PD Risk: A Case Control Study in Alaskan Natives		5a. CONTRACT NUMBER W81XWH-04-1-0490		
		5b. GRANT NUMBER		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Caroline M. Tanner, M.D., Ph.D. ctanner@theipi.org		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Parkinson's Institute 675 Almanor Avenue Sunnyvale, CA 94085		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research And Material Command Fort Detrick Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
13. SUPPLEMENTARY NOTES None				
14. ABSTRACT The intent of this proposal is to conduct a case-control study of Parkinson's disease (PD) among Alaska Natives to determine the association of exposure to polychlorinated biphenyl (PCBs) residues, organochlorine pesticides and methylmercury with PD. The hypothesis is that increased exposure to these compounds will be associated with an increased risk of PD. Exposure will be determined by direct measurement of serum levels, as these compounds are persistent in body tissues. In addition, lifelong exposure will be estimated by structured interview, including a dietary history with specific attention to intake of fish, marine mammals and wild game, known sources of bioconcentration of these environmentally persistent compounds. The project is being conducted in two phases. Phase 1 is a developmental period and is complete for study conduct statewide. The specific aspects of the study design were established, detailed protocols were developed, and Institutional Review Board (IRB) approval was obtained. Phase 2, conduct of the case-control study, is now in progress statewide.				
15. SUBJECT TERMS Parkinson's disease, Polychlorinated biphenyl, Organochlorine pesticides, Methylmercury, Alaska Natives, Neurodegeneration				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES 8
a. REPORT U	b. ABSTRACT U	c. THIS PAGE UU		
				19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	8
References.....	8
Appendices.....	8

A. Introduction

The intent of this proposal is to conduct a case control study of Parkinson's disease (PD) among Alaska Native people to determine the association of exposure to polychlorinated biphenyl (PCBs) residues, organochlorine pesticides, and methylmercury with PD. The hypothesis is that increased exposure to these compounds will be associated with an increased risk of PD. Exposure will be determined by direct measurement of serum levels, as these compounds are persistent in body tissues. In addition, lifelong exposure will be estimated by structured interviews, including a dietary history with specific attention to intake of fish, marine mammals and wild game, known sources of bioconcentration of these environmentally persistent compounds. The project is being conducted in two phases. Phase 1 was a developmental period and is complete. The specific aspects of the study design were established, detailed protocols were developed, and the necessary Institutional Review Board (IRB) approvals for the research were obtained. Phase 2, conduct of the case-control study, is now in progress.

B. Body

SCOPE OF WORK - PHASE 1

Task 1: Develop an ascertainment protocol using Indian Health Service (IHS) provider databases as the primary source, and identifying other possible sources of cases.

Task 2: Develop methods for identifying matched controls.

Accomplishments:

Approved methods were utilized to identify cases and controls for recruitment at the Alaska Native Medical Center (ANMC) in Anchorage during prior study years. During the past year, similar methods were adapted to ascertain and recruit cases and controls at clinics in the following locations statewide: Juneau, Sitka, Klawok, Metlakatla, Nome, Kotzebue, Barrow, and Dillingham.

Task 3: Develop a preliminary proposal for review by Alaska Native leaders. Subsequent detailed versions of the study protocol will be submitted for review in accordance with protocol.

Accomplishments:

The study protocol, data collection instruments, and informed consents were submitted and approved by all necessary regulatory boards (see Task 7) and the Human Research Protection Office (HRPO) Office of Research Protections (ORP) U.S. Army Medical Research and Materiel Command (USAMRMC) for study conduct at ANMC. The approved documents are being utilized to recruit, enroll, and collect data from study participants statewide.

Task 4: Establishing appropriate infrastructure and personnel in Alaska. This will include a physician/neurologist, project manager, and local contacts within each tribal group. In addition, preliminary training in epidemiologic research methods may be a necessary part of a feasibility assessment.

Accomplishments:

Dr. Trimble, our local neurologist, has been involved with the project since its inception. In April 2007 we hired an Alaska based project manager, Amy Wiita. Additionally, Monica Korell, who has been with the project since its inception, continues as the senior study manager. All members of the research team completed human subjects training and training in study specific data collection methods. The team members maintain regular contact and collegial working relationships with

representatives of the 12 tribal health organizations, clinic administrators, and health professionals working with the neurology clinics.

Task 5: Develop study instruments and a detailed protocol.

Accomplishments:

Drafts were completed during year 2. We developed a study protocol and study instruments for collecting detailed life histories with special focus on dietary, residential and occupational exposures. After receiving approval from institutional review boards, the HRPO ORP USAMRMC requested additional changes to the protocol. Those changes were implemented, resubmitted, and approved. Study activities are being conducted under the current approvals.

Task 6: Refining the study protocol and preparing the operations manual.

Accomplishments:

The study protocol was refined and approved for use in Anchorage as well as 8 of 10 regions outside the Anchorage basin. The operations manual was prepared.

Task 7: IRB approval of final protocols.

Accomplishments:

IRB approval to recruit in the ANMC in Anchorage was achieved January 16, 2008, and the study was initiated in Anchorage (see Table 1). In September 2009, we submitted the currently approved protocol and participant materials to all 10 regional tribal boards outside of Anchorage. We subsequently met with tribal boards and local clinic staff in order to describe the study hypotheses and protocol, and to answer any questions they might have. Reviews of the currently approved protocol are underway (n = 2) or complete (n = 8) at each of the 10 regional tribal boards outside of Anchorage (Table 3).

Table 1. Human Subject Approval Status

Institution	Review Board	Status
Parkinson's Institute	Western IRB	Approved
Alaska Native Medical Center	AK Area IRB	Approved
Pacific Health Research Institute	VA Pacific Islands Health Care System	Approved
University of California San Francisco	UCSF Committee on Human Research	Approved
USAMRMC	Office of Research Protections	Approved

Table 2. Anchorage Service Unit Tribal Health Boards

Institution	Review Board	Status
Alaska Native Medical Center	AK Native Tribal Health Consortium	Approved
Alaska Native Medical Center	SouthCentral Foundation	Approved

Table 3. Regional Tribal Health Boards (regions outside the Anchorage service unit)

Region Served	Review Board	Submission Status	Approval
Kotzebue	Maniilaq Association	Complete	Approved
Sitka, Juneau, Klawok	Southeast AK Regional Health Consortium	Complete	Approved
Fairbanks	Tanana Chiefs Council	Review pending	pending
Nome	Norton Sound Health Corporation	Complete	Approved
Bethel	Yukon Kuskokwim Health Corporation	Complete	pending
Kodiak	Kodiak Area Native Association	Complete	Approved
Dillingham	Bristol Bay Area Health Corporation	Complete	Approved
Barrow	Arctic Slope Native Association	Complete	Approved
Ketchikan	Ketchikan Indian Community	Complete	Approved
Metlakatla	Metlakatla Indian Community	Complete	Approved

SCOPE OF WORK - PHASE 2

Phase 2 was initiated in February 2008.
The goals of this phase are:

Task1: Identify approximately 50 cases of PD and 150 age matched participants without PD among the Native population in Alaska. This will be accomplished by working through tribal leaders, local health care providers and local contacts at the IHS to assist with identifying the most efficient and appropriate means of identifying cases and controls. Specifically, we will request assistance with gaining access to the IHS computerized medical record, the IHS hospital discharge data system, and pharmacy databases. These databases will be used to identify individuals with a diagnosis of PD and individuals on PD medications. Potential participants will be contacted by phone and administered a PD screening instrument. Those who agree to participate and who screen positively will be examined by a trained physician who will use standardized instruments for assessing Parkinson's disease (Unified

Parkinson's Disease Rating Scale, Hoehn and Yahr stage, etc.). Participants will be videotaped to allow expert confirmation of diagnosis. Control participants will be selected from the same population and similarly screened.

Accomplished:

Cases: We established a list of 10 International Classification of Disease (ICD-9) codes related to PD. Patient databases at all clinics where approval has been achieved are periodically searched for these codes. The outputs from the searches are compiled by Dr. Trimble to identify and prioritize suspect cases for study enrollment. To date, we have generated a list of 90 cases with a provisional PD diagnosis statewide. Efforts over the past year have focused on statewide case recruitment. In the past 12 months, case enrollment has tripled.

84 cases with a provisional PD diagnosis were screened (initial review of medical record to determine study eligibility)

- 18 Enrollment in progress
- 39 provided informed consent and are enrolled
 - 16 finished all parts of interview
 - 23 evaluations / interviews in progress
- 4 refusals
- 19 ineligible
- 4 on hold

Controls: Because control recruitment is linked to case enrollment, over the past 12 months we have targeted case enrollment on a statewide basis. We will focus on identifying and enrolling matched controls statewide during the next 12 months.

50 potential controls screened at ANMC

- 0 Enrollment in progress
- 34 provided informed consent and are enrolled
 - 33 have finished all parts of interview
 - 1 interview in progress
- 2 refusals
- 8 ineligible
- 6 on hold

Task 2: Draw blood from cases and controls to measure levels of PCBs, organochlorine pesticides and methyl mercury.

Accomplished:

Ongoing training is conducted to ensure the proper collection, shipment, and processing of blood samples. As we expand to enroll participants statewide, we have established a network of clinic phlebotomists to be on-call for study blood draws. After labeling, the blood samples are shipped overnight to the Parkinson's Institute laboratory for processing and storage. To date, samples from 65 subjects have been collected, shipped, and processed.

Task 3: Administer a structured interview to cases and controls to identify information important to the characterization of PCB, organochlorine pesticides and methyl mercury exposure (life time diet, occupation, place of residence, recreational activities) or identifying potential confounders (smoking cigarettes, drinking coffee, alcohol).

Accomplished:

Of the 73 subjects enrolled to date, 48 interviews have been completed and 25 are in-progress.

Task 4. Estimate logistic regression models adjusted for age and other potential confounders to determine the odds of PD among those with high levels of PCB , organochlorine pesticides and methyl mercury exposure, individually and in combination, relative to the odds of PD among those with no or low levels of exposure the toxicants.

Accomplished:

Databases have been developed at the Parkinson's Institute, and procedures for data entry and quality control implemented. Data analysis will not be initiated until all data collection is complete.

C. Key Research Accomplishments

- Held bi-monthly, face-to-face meetings with collaborators in AK to discuss study progress, challenges, and potential refinement to methods of case ascertainment.
- Case ascertainment, review of potential case medical records by Dr. Trimble, enrollment and data collection continued in Anchorage and was expanded to Juneau, Sitka, Klawok, Metlakatla, Nome, Kotzebue, Barrow, and Dillingham. Case enrollment tripled in the past 12 months.
- Diagnostic evaluations and risk factor interviews were expanded from Anchorage to statewide regions including Juneau, Sitka, Klawok, Metlakatla, Nome, Kotzebue, Barrow, and Dillingham.
- Continued in-person presentations and face to face meetings with tribal health organizations, clinic administrators, and health professionals working with the neurology clinics to give study overviews and address concerns and interests unique to each regional clinic. 80% of the tribal board approvals were received and 20% are still being negotiated.
- Requested and received an extension of the project through April 2014.

D. Reportable Outcomes

We will not have reportable outcomes until all data collection is finished statewide.

E. Conclusions

Following the completion of subject enrollment, data and sample collection, and analysis, it will be possible to draw relevant scientific conclusions. Based on study progress to date, we are confident that we will successfully meet our PD ascertainment goal of 50 individuals.

F. References

None

G. Appendices

None